Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

2.0K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluating the Impact of Different Natural History Modeling Methods on Cost-Effectiveness Decisions: A Case Study in Duchenne Muscular Dystrophy.

MDM policy & practice·2026
Same author

Black Hole Spectroscopy and Tests of General Relativity with GW250114.

Physical review letters·2026
Same author

Patient and Public Involvement (PPI) in Secondary Data Analysis: Protocol for a Targeted Review.

Health expectations : an international journal of public participation in health care and health policy·2025
Same author

GW250114: Testing Hawking's Area Law and the Kerr Nature of Black Holes.

Physical review letters·2025
Same author

Liver function in X-linked myotubular myopathy and autosomal dominant centronuclear myopathy: Data of the unite-CNM study.

Journal of neuromuscular diseases·2025
Same author

Correction: Developing a Natural History Model for Duchenne Muscular Dystrophy.

PharmacoEconomics - open·2024
Same journal

Cost-Effectiveness of Tezepelumab Versus Omalizumab in Patients with Severe Uncontrolled Allergic Asthma in Spain.

PharmacoEconomics - open·2026
Same journal

Availability, Prices, and Affordability of Immune Checkpoint Inhibitors: A Cross-Sectional Study in Anhui Province, China.

PharmacoEconomics - open·2026
Same journal

Estimating the Long-Term Clinical and Economic Impact of Universal Varicella Vaccination in Portugal Using a Dynamic Transmission Model.

PharmacoEconomics - open·2026
Same journal

A Targeted Review of Available Data Sources to Support Evidence-Informed Decisions: Implications for Health Technology Assessment in South Africa.

PharmacoEconomics - open·2026
Same journal

Integrating Structured Expert Elicitation with External Evidence to Inform Earlier Reimbursement Decisions: A Norwegian Case Study of Selpercatinib for Non-Small Cell Lung Cancer.

PharmacoEconomics - open·2026
Same journal

Health Utility Values Measured by EQ-5D in Breast Cancer From Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis Protocol.

PharmacoEconomics - open·2026
See all related articles

Related Experiment Video

Updated: Jul 9, 2025

Assessing Functional Performance in the Mdx Mouse Model
10:32

Assessing Functional Performance in the Mdx Mouse Model

Published on: March 27, 2014

32.6K

Developing a Natural History Model for Duchenne Muscular Dystrophy.

Jonathan Broomfield1, M Hill2, F Chandler3,4

  • 1University of Leicester, Leicester, UK. jb781@leicester.ac.uk.

Pharmacoeconomics - Open
|November 29, 2023
PubMed
Summary
This summary is machine-generated.

A new natural history model (NHM) for Duchenne muscular dystrophy (DMD) estimates disease progression and survival, aiding economic evaluations for new treatments.

More Related Videos

Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy
09:18

Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy

Published on: January 12, 2019

10.4K
Isometric and Eccentric Force Generation Assessment of Skeletal Muscles Isolated from Murine Models of Muscular Dystrophies
14:10

Isometric and Eccentric Force Generation Assessment of Skeletal Muscles Isolated from Murine Models of Muscular Dystrophies

Published on: January 31, 2013

33.0K

Related Experiment Videos

Last Updated: Jul 9, 2025

Assessing Functional Performance in the Mdx Mouse Model
10:32

Assessing Functional Performance in the Mdx Mouse Model

Published on: March 27, 2014

32.6K
Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy
09:18

Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy

Published on: January 12, 2019

10.4K
Isometric and Eccentric Force Generation Assessment of Skeletal Muscles Isolated from Murine Models of Muscular Dystrophies
14:10

Isometric and Eccentric Force Generation Assessment of Skeletal Muscles Isolated from Murine Models of Muscular Dystrophies

Published on: January 31, 2013

33.0K

Area of Science:

  • Biomedical Informatics
  • Disease Modeling
  • Health Economics

Background:

  • Duchenne muscular dystrophy (DMD) requires robust tools for health technology assessments.
  • Existing models lack a comprehensive, patient-centric view of disease trajectory.
  • Project HERCULES aims to develop data-informed models for DMD treatment evaluation.

Purpose of the Study:

  • To develop a patient-centric, data-informed natural history model (NHM) for Duchenne muscular dystrophy (DMD).
  • To estimate the lifetime disease trajectory of DMD patients under current standard of care.
  • To support future economic evaluations and health technology assessments for novel DMD therapies.

Main Methods:

  • Pooled multiple datasets, including the Critical Path Institute Duchenne Regulatory Science Consortium (D-RSC) database.
  • Defined health states based on clinical trial outcomes, real-world practice, and expert input.
  • Supplemented data with expert elicitation and a systematic literature review and meta-analysis of mortality.

Main Results:

  • The NHM incorporates ambulatory, transfer, and non-ambulatory phases, detailing functional decline.
  • Patients spend approximately 9.5 years in ambulatory states, 1.5 years in the transfer state.
  • Median predicted survival for DMD patients is estimated at 34.8 years.

Conclusions:

  • The developed NHM provides a detailed disease pathway for DMD, including the critical transfer state.
  • This model can enhance economic evaluations by incorporating a lifetime time horizon for DMD.
  • The NHM will aid in identifying future research priorities for Duchenne muscular dystrophy.